Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

SNDXAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ717.00− 1.19%S&P 500 · SPY769.88− 0.31%Dow Jones · DIA523.25− 0.27%Russell 2000 · IWM284.95+ 1.30%

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo09:00Yesterday

07:00-10:00Oct 262 Stories

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo09:00SNDX−1.3%
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 2, 2026. The live audio webcast and accompanying
Yahoo07:00SNDX−1.3%

16:00Oct 151 Story

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME’s annual list of the Best Inventions features 300 extraordinary inventions changing lives. To compile this year's list, TIME solicit
Yahoo16:01SNDX−1.3%